Days Sales in Receivables: The average number of days it takes to collect outstanding receivable amounts from customers. Calculated as: Number of Days in Period / Receivable Turnover
Xilio Therapeutics, Inc. (XLO) had Days Sales in Receivables of 82.61 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$19.07M |
|
$-16.29M |
|
-- |
|
$19.07M |
|
$21.00M |
|
$-1.93M |
|
$-14.36M |
|
$-16.29M |
|
$-16.29M |
|
$-16.29M |
|
$-16.29M |
|
$-16.29M |
|
$-16.29M |
|
$-1.93M |
|
$-1.59M |
|
144.11M |
|
144.11M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$124.09M |
|
$3.68M |
|
$9.61M |
|
$133.69M |
|
$56.40M |
|
-- |
|
$85.39M |
|
$141.79M |
|
$-8.10M |
|
$-8.10M |
|
$-8.10M |
|
51.83M |
|
| Cash Flow Statement Financials | |
$-2.99M |
|
$-0.42M |
|
$51.91M |
|
$57.07M |
|
$105.56M |
|
$48.49M |
|
$4.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-10.12% |
|
-10.12% |
|
-- |
|
-85.42% |
|
-85.42% |
|
$-3.42M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
-- |
|
1.09 |
|
|
Days Sales in Receivables |
82.61 |
201.20% |
|
201.20% |
|
-12.18% |
|
201.20% |
|
$-0.16 |
|
$-0.02 |
|
$-0.02 |
|